Doug represented a Fortune 50 pharmaceutical company in antitrust litigation against a competitor, suing over an allegedly illegal tying arrangement involving the two companies’ oncology chemotherapy adjunct drugs. We acted as local counsel with a major New York firm. The matter involved a state-of-the-art preliminary injunction trial in federal court in New Jersey, and eventually settled for $200 million.